NCT05877690

Brief Summary

to compare the safety and efficacy of spinal anesthesia using Hyperbaric Prilocaine 2% versus Hyperbaric Bupivacaine 0.5% for patients with peripheral vascular disease and cardiac dysfunction.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 23, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

May 26, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

October 1, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

May 26, 2023

Status Verified

March 1, 2023

Enrollment Period

1 year

First QC Date

February 23, 2023

Last Update Submit

May 17, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Monitoring blood pressure both systole and diastole

    When, how the chang in the baseline

    75 minutes

Study Arms (2)

Group M

EXPERIMENTAL
Drug: Bupivacaine 0.5% Injectable Solution

Group p

EXPERIMENTAL
Drug: Prilocaine Hydrochloride 2% Injection

Interventions

Patient will be received the drug intrathecal

Also known as: Marcaine
Group M

Patient will be received the drug intrathecal

Also known as: Takipril
Group p

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients of aged \>18 years old. Both sexes, males and females.
  • The time of surgery does not exceed 75 min.
  • Compensated cardiac dysfunction
  • ASA physical status: II- IV

You may not qualify if:

  • refusal
  • Allergy to the studied drugs.
  • Patients with contraindications to spinal anesthesia.
  • Patients with advanced decompensated cardiac, renal, hepatic disease
  • Coagulopathy or thrombocytopenia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assuit university

Asyut, Assuit, Egypt

RECRUITING

MeSH Terms

Interventions

BupivacainePrilocaineInjections

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesDrug Administration RoutesDrug TherapyTherapeutics

Study Officials

  • Ekram Abdullah, Professor

    Assiut University

    STUDY CHAIR

Central Study Contacts

Zahwa Yehya, Master

CONTACT

Saeid Metwally

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

February 23, 2023

First Posted

May 26, 2023

Study Start

October 1, 2023

Primary Completion

October 1, 2024

Study Completion

December 1, 2024

Last Updated

May 26, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations